Earnings summaries and quarterly performance for OPKO HEALTH.
Executive leadership at OPKO HEALTH.
Board of directors at OPKO HEALTH.
Research analysts who have asked questions during OPKO HEALTH earnings calls.
Edward Tenthoff
Piper Sandler Companies
4 questions for OPK
Also covers: ARVN, ARWR, CAPR +14 more
Yi Chen
H.C. Wainwright & Co.
4 questions for OPK
Also covers: ANGO, APDN, BLFS +22 more
Michael Petusky
Barrington Research
3 questions for OPK
Also covers: ANIK, HAE, HSIC +8 more
Yale Jen
Laidlaw & Company (UK) Ltd.
3 questions for OPK
Also covers: AFMD, ALDX, ARCT +13 more
James Stamos
Jefferies Financial Group Inc.
2 questions for OPK
Maurice Raycroft
Jefferies Financial Group
2 questions for OPK
Also covers: ABEO, AFMD, ALNY +14 more
Destiny Buch
Ladenburg Thalmann & Co. Inc.
1 question for OPK
Also covers: BNGO, CCLD, NBY +1 more
Recent press releases and 8-K filings for OPK.
OPKO Health Reports Q3 2025 Results, Completes Oncology Division Sale, and Announces Regeneron Collaboration
OPK
Earnings
M&A
Share Buyback
- OPKO Health completed the sale of BioReference Health's oncology division, receiving $192.5 million at closing and an additional $32.5 million in a performance-based earnout, aiming to streamline its lab business.
- The company reported a Q3 2025 consolidated operating income of $48.1 million and net income of $21.6 million, or $0.03 per basic and diluted share.
- OPKO Health announced a research collaboration and license agreement with Regeneron, potentially yielding over $1 billion in milestone payments and tiered royalties for the development of multi-specific antibodies.
- The company repurchased 11.1 million shares during Q3 2025, with $126 million remaining under its share repurchase program as of September 30.
- For Q4 2025, OPKO Health expects total revenue between $135 million and $140 million and anticipates achieving break-even operating results.
Oct 29, 2025, 8:30 PM
OPKO Health Reports Q3 2025 Financial Results and Strategic Business Highlights
OPK
Earnings
M&A
Share Buyback
- OPKO Health, Inc. reported Q3 2025 consolidated total revenues of $151.7 million and net income of $21.6 million, or $0.03 per diluted share, which included a $101.6 million gain from the sale of BioReference oncology assets.
- The company entered a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies, with potential milestone payments exceeding $200 million for each program and an overall collaboration value potentially exceeding $1 billion.
- OPKO completed the sale of BioReference Health's oncology and related clinical assets to Labcorp for $225 million, with $192.5 million paid at closing, and has repurchased approximately $73.8 million of common stock under its program, with $126.2 million remaining authorized.
- The FDA approved a supplemental application for the 4Kscore® Test in July 2025, enabling its performance without digital rectal examination information.
Oct 29, 2025, 8:11 PM
OPKO Health Reports Q3 2025 Financial Results, Announces Regeneron Collaboration and Asset Sale
OPK
Earnings
M&A
New Projects/Investments
- OPKO Health reported total revenues of $151.7 million for the third quarter of 2025, compared to $173.6 million for the same period in 2024, with net income of $21.6 million or $0.03 per diluted share.
- The company completed the sale of BioReference Health's oncology and related clinical assets to Labcorp for $225 million, receiving $192.5 million at closing, and intends to utilize a portion of the proceeds for its share repurchase program.
- OPKO entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies, with potential milestone payments that could exceed $1 billion if multiple products are successful.
- The FDA approved a supplemental application for the 4Kscore® Test, allowing its performance without digital rectal examination information.
Oct 29, 2025, 8:05 PM
OPKO Health's ModeX Therapeutics Announces Collaboration with Regeneron
OPK
New Projects/Investments
- ModeX Therapeutics, an OPKO Health company, has entered a license and collaboration agreement with Regeneron Pharmaceuticals Inc. to discover and develop multispecific antibodies for several therapeutic indications.
- Under the terms of the agreement, ModeX will receive an upfront payment of $7 million.
- The collaboration has a potential total value exceeding $1 billion if multiple products are successful, with potential future payments exceeding $200 million per selected molecule and tiered global net sales royalties up to low double digits.
- Regeneron will fund and lead all preclinical, clinical development, and commercialization activities for any products it elects to advance.
Oct 29, 2025, 12:00 PM
OPKO Health Completes Sale of BioReference Health's Oncology and Clinical Testing Businesses to Labcorp
OPK
M&A
Share Buyback
- On September 15, 2025, OPKO Health, Inc. completed the sale of select oncology and oncology-related clinical testing services businesses of its subsidiary, BioReference Health, to Labcorp.
- The total purchase price for the transaction is up to $225 million, including $192.5 million paid at closing and up to $32.5 million in a contingent earnout based on performance.
- BioReference Health will retain its core clinical testing operations in the New York and New Jersey region and its 4Kscore® Test franchise, which generated approximately $300 million in revenue for 2024.
- OPKO intends to utilize a portion of the proceeds from the sale to fund its recently expanded share repurchase authorization.
Sep 15, 2025, 8:02 PM
Entera Bio and OPKO Health Report Positive Preclinical Data for Oral GLP-2 Tablet
OPK
Product Launch
New Projects/Investments
- Entera Bio, in collaboration with OPKO Health, presented positive preclinical pharmacokinetic data for their oral GLP-2 analog, OPK-8801003, for Short Bowel Syndrome (SBS) at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress on September 15, 2025.
- The OPK-8801003 GLP-2 tablet demonstrated an extended half-life of approximately 15 hours in minipigs, an 18-fold improvement over teduglutide, and robust oral bioavailability with peak plasma concentrations reaching ~200 ng/ml (Cmax).
- This oral tablet candidate aims to provide a less-invasive administration for the approximately 30,000 SBS patients who currently rely on daily injections of Gattex®, which generates approximately $800 million in annual sales.
Sep 15, 2025, 1:00 PM
Quarterly earnings call transcripts for OPKO HEALTH.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more